Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,523 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,523 shares of Natera stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total transaction of $139,171.74. Following the transaction, the chief financial officer now directly owns 73,039 shares in the company, valued at approximately $6,674,303.82. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The stock was sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The stock was sold at an average price of $70.03, for a total transaction of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total transaction of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The stock was sold at an average price of $65.09, for a total transaction of $210,566.15.

Natera Stock Performance

Natera stock traded up $2.43 during mid-day trading on Tuesday, reaching $91.04. The company’s stock had a trading volume of 1,178,233 shares, compared to its average volume of 1,470,075. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $98.82. The company has a market capitalization of $10.99 billion, a P/E ratio of -24.02 and a beta of 1.37. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. The firm’s fifty day moving average price is $86.40 and its two-hundred day moving average price is $66.49.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Sell-side analysts predict that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Natera by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after purchasing an additional 588,147 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Natera by 0.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,556,792 shares of the medical research company’s stock valued at $334,388,000 after purchasing an additional 67,102 shares in the last quarter. Kynam Capital Management LP lifted its holdings in shares of Natera by 3.6% during the 3rd quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company’s stock worth $132,912,000 after acquiring an additional 103,668 shares during the last quarter. RTW Investments LP lifted its holdings in shares of Natera by 1.5% during the 3rd quarter. RTW Investments LP now owns 2,651,783 shares of the medical research company’s stock worth $117,341,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Natera by 52.0% during the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock worth $111,930,000 after acquiring an additional 865,404 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NTRA has been the subject of several research analyst reports. BTIG Research raised their price target on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. Craig Hallum initiated coverage on shares of Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 price target for the company. The Goldman Sachs Group raised their price target on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Stephens restated an “overweight” rating and set a $78.00 price target on shares of Natera in a research note on Tuesday, January 30th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.